RBC Capital analyst Gregory Renza maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report) on March 4 and set a price target of $11.00. The company’s shares closed
RBC Capital analyst Gregory Renza maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report) on March 4 and set a price target of $11.00. The company’s shares closed
This week, several major companies will be reporting earnings. Among them are Nio (NIO), CrowdStrike Holdings (CRWD), Costco (COST), Broadcom (AVGO) and ChargePoint Holdings (CHPT). Ahead of this week’s major
Inovio Pharmaceuticals (INO) is scheduled to report 4th quarter earnings on 03/06/2024, after the market closes. Regarding Q4 estimates, Wall Street analysts expect Inovio Pharmaceuticals to post earnings of -$1.19
Inovio Pharmaceuticals (INO) has released an update to notify the public and investors about corporate charter and bylaws modifications. Inovio Pharmaceuticals, Inc. implemented a 1-for-12 reverse stock split on January
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by